pI: 9.4705 |
Length (AA): 505 |
MW (Da): 57708 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 6 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 422 | 2etr (A) | 56 | 404 | 18.00 | 0 | 1 | 0.69 | 0.54 |
19 | 341 | 1csn () | 9 | 288 | 48.00 | 0 | 1 | 1.11 | -0.67 |
103 | 333 | 1u46 (A) | 169 | 387 | 22.00 | 0 | 1 | 0.73 | -0.69 |
16 | 428 | 5czo (A) | 2 | 383 | 43.00 | 0 | 1 | 1.18772 | -0.16 |
17 | 343 | 4kb8 (A) | 4 | 285 | 56.00 | 0 | 1 | 1.02742 | -0.16 |
110 | 334 | 4hzr (A) | 176 | 388 | 20.00 | 0.00000000023 | 1 | 0.722445 | -0.63 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | metacyclic. | Fernandes MC |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | amastigotes. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_154588)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.25.2430 | casein kinase I, putative |
Leishmania donovani | LdBPK_251640.1 | casein kinase I, putative |
Leishmania infantum | LinJ.25.1640 | casein kinase I, putative |
Leishmania major | LmjF.25.1580 | casein kinase I, putative |
Leishmania mexicana | LmxM.25.1580 | casein kinase I, putative |
Trypanosoma brucei gambiense | Tbg972.3.1460 | casein kinase 1, putative |
Trypanosoma brucei | Tb927.3.1630 | casein kinase 1, putative |
Trypanosoma congolense | TcIL3000_3_730 | casein kinase 1, putative |
Trypanosoma cruzi | TcCLB.510089.170 | casein kinase I, putative |
Trypanosoma cruzi | TcCLB.510421.180 | casein kinase I, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.3.1630 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.3.1630 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.3.1630 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.3.1630 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania major | No drug identifiers listed for this gene. | |
Annotator: | crowther@u.washington.edu. | Comment: | Drug: 188343-77-3; Drug: 191030-70-3; Drug: 762172-81-6; Drug: 480453-85-8. chemical inhibitors reduced casein kinase activity and growth of promastigotes. | References: | 16890941 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania major | No drug identifiers listed for this gene. |
Annotator: | crowther@u.washington.edu. | Comment: | Drug: 188343-77-3; Drug: 191030-70-3; Drug: 762172-81-6; Drug: 480453-85-8. chemical inhibitors reduced casein kinase activity and growth of promastigotes. | References: | 16890941 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.7
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 22.9% | 306 aa | Compounds | References |
Bos taurus | Casein kinase I isoform alpha | 325 aa | 47.2% | 320 aa | Compounds | References |
Sus scrofa | Casein kinase I isoform alpha | 125 aa | 44.3% | 167 aa | Compounds | References |